Value and Access
The healthcare landscape is increasingly being assessed on the value of its contribution; how this shift will impact all stakeholders – providers, payers, biopharma and ultimately patients – needs to be assessed and understood. By bringing together global regulators, industry leaders, patients and payers the Value and Access track will promote discussions and address questions including:
- Which information and evidence is being used to define value? Who should be a part of the decision-making process?
- What is the best way to leverage real world evidence in value dossiers and propositions?
- What role will indication-based labels and regulator-payer discussions play as the health technologies continue to evolve?
- How best to design evidence packages and discuss new technologies such as histology-independent labels with decision makers?
Who is This Track Designed For?
Professionals involved in patient access, market access, regulatory intelligence, health technology assessment, outcomes research, health economy, HTA bodies, academics, payers, providers, regulatory strategy, real world evidence professionals, solution providers and consultants.